Policy
Older, frail patients are still being let down by the regulators
Hans Wildiers is frustrated. “This drug is well-tolerated in older persons – this is a very frequent conclusion in publications. And it is often not a correct conclusion,” says the…
Not too little, not too much… a lesson for cancer prevention from ancient civilisations
“If we could give every individual the right amount of nourishment and exercise, not too little and not too much, we would have found the safest way to health.” This…
Beating cancer is complex – our messaging must be clear
A window of opportunity is opening up across Europe to reverse the ever-rising trend of new cancers and improve outcomes for patients everywhere. It’s been brought about in part by…
Croatia’s cancer plan showcases the value of European cancer collaboration
Croatia has caught up with the rest of the EU in adopting a national cancer control plan. Sophie Fessl looks at how using EU guidance drawn from experiences of other…
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to…
Could covid-19 boost interest in drug repurposing in oncology?
Could the frantic search for drugs to treat patients severely affected by the covid-19 virus be a shot in the arm for new cancer treatments? There have been many headlines…
On a mission to beat cancer
One small step for man, one giant leap for mankind – the words Neil Armstrong pronounced as he completed humankind’s first mission to the moon, will – if the European…
How retractions are helping cancer research
In 2015, cancer researcher Anil Potti – back then associated with Duke University in Durham, North Carolina – was found guilty of research misconduct by a US federal investigation led…